Summary & Overview
CPT 53220: Urethral Tumor Excision or Destruction
CPT code 53220 represents surgical management of malignant tumors of the urethra via partial or complete excision or electrocautery destruction, performed to remove cancerous tissue and improve urinary function. This code captures a focused urologic oncologic procedure that has implications for specialty surgical billing, facility resources, and post-procedure care needs nationwide. Payors commonly involved in coverage and payment for this service include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical intent and service setting, common modifiers and billing practice context, and national payer considerations. The publication summarizes benchmarks where available, highlights coding and documentation points relevant to reimbursement and utilization, and outlines clinical context including indications and expected sites of service. Data not available in the input are identified explicitly. This resource is intended to support billing professionals, urology providers, and policy analysts in understanding how CPT code 53220 is described, where it is commonly performed, which major payors are relevant, and what topics (benchmarks, policy updates, clinical context) are typically covered in more detailed payer or facility analyses.
Billing Code Overview
CPT code 53220 describes a procedure in which the provider partially or completely excises a tumor in the urethra or exposes the tumor to electric current to destroy it. The procedure is performed to remove a malignant tumor and improve urination.
-
Service type: Surgical tumor excision or destruction of urethral tumor
-
Typical site of service: Hospital operating room or ambulatory surgery center where endoscopic or transurethral tumor excision/destruction is performed
Clinical & Coding Specifications
Clinical Context
A 68-year-old male presents with progressive urinary obstruction, urinary frequency, and intermittent hematuria. Cystoscopic evaluation identifies a urethral mass consistent with a suspected or biopsy-proven malignant urethral tumor causing obstructive symptoms. After preoperative assessment and informed consent, the urologist schedules a transurethral excision and/or fulguration of the urethral tumor under general or spinal anesthesia. The clinical workflow includes preoperative imaging and urine studies, operating-room cystoscopic tumor visualization, partial or complete tumor excision and electrocautery fulguration as indicated, hemostasis, possible placement of a urinary catheter for short-term drainage, and postoperative monitoring for bleeding, infection, and urinary retention. Pathology is sent if tissue is obtained, and follow-up includes wound care, urine flow assessment, and oncologic planning if malignancy is confirmed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Principal physician of record | Use when the reporting surgeon is the primary physician performing the procedure. |
22 | Increased procedural services | Use when the procedure requires substantially greater work than usual (extensive tumor burden or complex excision). |